Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01213810

Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study

Status
Withdrawn
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
0 (actual)
Sponsor
University of Zurich · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The goal is to demonstrate the immunogenicity and safety of Zostavax® in HIV positive individuals. Study participants are stratified into different patient groups according to their CD4 cell count, viral load and HIV Status. * Trial with medicinal product * Trial with immunomodulatory product / biological

Conditions

Interventions

TypeNameDescription
BIOLOGICALZostavaxBiological/Vaccine

Timeline

Start date
2010-12-01
Primary completion
2011-12-01
Completion
2012-06-01
First posted
2010-10-04
Last updated
2013-03-01

Source: ClinicalTrials.gov record NCT01213810. Inclusion in this directory is not an endorsement.